What Keeps a Clinical Pharmacist Up at Night? Unanswered Questions
Dr. Thigpen explores some of the neonatal disease processes that continue to frustrate clinicians despite continual research. He takes a brief look at historical therapy and then discuss the current regimens as well as the forecast of future treatment. Topics will include NEC, BPD, HIE, and pulmonary hypertension, among others.
Describe the common therapies that may have an impact on the long-term neurological development of ex-preemies.
Discuss the adverse consequences of neonatal antibiotic exposure and what we can do about it.
Summarize what the current literature provides on the outcomes of neonatal abstinence syndrome.
Antenatal Late Preterm Steroids and Neonatal Effects of Antenatal Magnesium Sulfate
Dr. Johnson explores the current recommendations for administration of steroids to the mother for planned delivery prior to 37 completed weeks, including the known benefits, contraindications, and potential complications of broadening the recommendations for steroids to the late preterm, 34–36 6/7 weeks. She also presents the indications for antenatal magnesium sulfate administration including for neuroprotection of the very low birth weight infant and discusses the potential benefits and complications.
List the evidenced-based outcome goals for administering antenatal steroids to the mother with an anticipated late preterm delivery.
Describe the contraindications for administering antenatal steroids to the mother with an anticipated late preterm delivery.
Identify the evidenced-based indications for magnesium sulfate use in obstetrics and the potential complications for the neonate.
Associate Professor of Pharmacy Practice,
ETSU Bill Gatton College of Pharmacy